



MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION
(a/k/a The Lustgarten Foundation for Pancreatic Cancer Research)

Financial Statements

June 30, 2020 and 2019

(With Independent Auditors' Report Thereon)



KPMG LLP
345 Park Avenue
New York, NY 10154-0102

Independent Auditors' Report

To the Board of Directors
Marc Lustgarten Pancreatic Cancer Foundation:

We have audited the accompanying financial statements of the Marc Lustgarten Pancreatic Cancer Foundation (a/k/a The Lustgarten Foundation for Pancreatic Cancer Research) (the Foundation), which comprise the statements of financial position as of June 30, 2020 and 2019, and the related statements of activities, functional expenses, and cash flows for the years then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the organization's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the organization's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Marc Lustgarten Pancreatic Cancer Foundation as of June 30, 2020 and 2019, and the changes in its net assets and its cash flows for the years then ended in accordance with U.S. generally accepted accounting principles.

KPMG LLP

May 14, 2021

MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION
(a/k/a The Lustgarten Foundation for Pancreatic Cancer Research)

Statements of Financial Position

June 30, 2020 and 2019

Assets	2020	2019
Cash and cash equivalents	\$ 1,910,337	5,845,815
Investments (note 4)	87,982,180	80,371,409
Contributions receivable (note 3)	318,852	12,638,779
Prepaid expenses and other assets	174,487	231,411
Software, furniture, and equipment, net of accumulated depreciation of \$208,053 and \$135,843 in 2019	<u>165,524</u>	<u>236,334</u>
Total assets	<u>\$ 90,551,380</u>	<u>99,323,748</u>
Liabilities and Net Assets		
Liabilities:		
Accounts payable and accrued expenses	\$ 478,590	816,700
Deferred revenue	480,772	312,614
Grants payable	8,774,834	7,539,230
Deferred rent obligation (note 5)	<u>76,877</u>	<u>65,649</u>
Total liabilities	<u>9,811,073</u>	<u>8,734,193</u>
Net assets:		
Without donor restrictions (note 5):		
Board-designated fund for administrative expenses	17,888,840	21,280,960
Reserved for conditional grants	43,292,539	29,710,588
Reserved for research	<u>19,194,928</u>	<u>39,542,362</u>
Total without donor restrictions	80,376,307	90,533,910
With donor restrictions (note 7)	<u>364,000</u>	<u>55,645</u>
Total net assets	<u>80,740,307</u>	<u>90,589,555</u>
Total liabilities and net assets	<u>\$ 90,551,380</u>	<u>99,323,748</u>

See accompanying notes to financial statements.

MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION
(a/k/a The Lustgarten Foundation for Pancreatic Cancer Research)

Statement of Activities

Year ended June 30, 2020

	Without donor restrictions	With donor restrictions	Total
Revenue:			
Contributions (note 3)	\$ 9,162,625	364,000	9,526,625
Special events, net of costs of direct benefits to donors of \$219,523	3,519,808	—	3,519,808
Contributed media and services (note 2)	3,946,136	—	3,946,136
Dividends and interest, net of investment fees	1,773,168	—	1,773,168
Royalties	7,855	—	7,855
Total revenue	18,409,592	364,000	18,773,592
Net assets released from donor restrictions (note 7)	55,645	(55,645)	—
Total revenue and other support	18,465,237	308,355	18,773,592
Expenses:			
Program services:			
Research	19,760,631	—	19,760,631
Public education and information (note 2)	4,739,143	—	4,739,143
Professional education	246,644	—	246,644
Total program services	24,746,418	—	24,746,418
Supporting services:			
Management and general	1,094,488	—	1,094,488
Fund-raising	2,828,833	—	2,828,833
Total supporting services	3,923,321	—	3,923,321
Total expenses	28,669,739	—	28,669,739
(Deficiency) excess of revenue and other support over expenses	(10,204,502)	308,355	(9,896,147)
Net appreciation in fair value of investments	46,899	—	46,899
(Decrease) increase in net assets	(10,157,603)	308,355	(9,849,248)
Net assets at beginning of period	90,533,910	55,645	90,589,555
Net assets at end of period	\$ 80,376,307	364,000	80,740,307

See accompanying notes to financial statements.

MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION
(a/k/a The Lustgarten Foundation for Pancreatic Cancer Research)

Statement of Activities

Year ended June 30, 2019

	Without donor restrictions	With donor restrictions	Total
Revenue:			
Contributions (note 3)	\$ 9,862,020	1,476,274	11,338,294
Special events, net of costs of direct benefits to donors of \$371,093	4,631,062	—	4,631,062
Contributed media and services (note 2)	10,331,929	—	10,331,929
Dividends and interest, net	1,654,262	—	1,654,262
Royalties	101,120	—	101,120
Total revenue	26,580,393	1,476,274	28,056,667
Net assets released from donor restrictions (note 7)	8,667,860	(8,667,860)	—
Total revenue and other support	35,248,253	(7,191,586)	28,056,667
Expenses:			
Program services:			
Research	24,673,145	—	24,673,145
Public education and information (note 2)	11,401,426	—	11,401,426
Professional education	261,711	—	261,711
Total program services	36,336,282	—	36,336,282
Supporting services:			
Management and general	1,399,271	—	1,399,271
Fund-raising	2,178,985	—	2,178,985
Total supporting services	3,578,256	—	3,578,256
Total expenses	39,914,538	—	39,914,538
Deficiency of revenue and other support over expenses	(4,666,285)	(7,191,586)	(11,857,871)
Net appreciation in fair value of investments	4,350,528	—	4,350,528
Decrease in net assets	(315,757)	(7,191,586)	(7,507,343)
Net assets at beginning of period	90,849,667	7,247,231	98,096,898
Net assets at end of period	\$ 90,533,910	55,645	90,589,555

See accompanying notes to financial statements.

MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION
(a/k/a The Lustgarten Foundation for Pancreatic Cancer Research)

Statement of Functional Expenses

Year ended June 30, 2020

	Program services				Supporting services			Total expenses
	Research	Public education and information	Professional education	Total	Management and general	Fund-raising	Total	
Grants expense	\$ 18,894,873	—	—	18,894,873	—	—	—	18,894,873
Research support	—	—	40,000	40,000	—	—	—	40,000
Strategic planning	—	—	—	—	—	—	—	—
Contributed media and services (note 2)	—	3,573,393	—	3,573,393	290,061	82,682	372,743	3,946,136
Salaries, professional services and related costs	710,860	858,213	120,878	1,689,951	584,975	1,109,828	1,694,803	3,384,754
Public Information Costs	—	103,831	—	103,831	500	434,843	435,343	539,174
Supplies and mail	24,329	40,548	24,329	89,206	32,438	81,096	113,534	202,740
Meetings, travel and related costs	10,196	5,098	—	15,294	20,391	66,271	86,662	101,956
Insurance	7,870	7,870	1,968	17,708	6,303	15,740	22,043	39,751
Printing	17,685	23,581	—	41,266	47,163	58,950	106,113	147,379
Depreciation	8,665	14,442	8,665	31,772	11,554	28,884	40,438	72,210
Marketing and advertising	—	—	—	—	—	535,698	535,698	535,698
Rent	37,055	37,055	9,264	83,374	27,791	74,111	101,902	185,276
Utilities and maintenance	10,077	10,077	2,519	22,673	7,558	20,153	27,711	50,384
Bank and credit card fees	—	—	—	—	13,726	190,507	204,233	204,233
Information technology and Web site	30,158	50,263	30,158	110,579	40,210	100,526	140,736	251,315
Other	8,863	14,772	8,863	32,498	11,818	29,544	41,362	73,860
Total expenses	\$ 19,760,631	4,739,143	246,644	24,746,418	1,094,488	2,828,833	3,923,321	28,669,739
Direct benefits to donors								219,523
Total expenses and direct benefits to donors								\$ 28,889,262

See accompanying notes to financial statements.

MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION
(a/k/a The Lustgarten Foundation for Pancreatic Cancer Research)

Statement of Functional Expenses

Year ended June 30, 2019

	Program services				Supporting services			Total expenses
	Research	Public education and information	Professional education	Total	Management and general	Fund-raising	Total	
Grants expense	\$ 23,777,569	—	—	23,777,569	—	—	—	23,777,569
Research support	—	—	48,813	48,813	—	268	268	49,081
Strategic planning	—	36,161	—	36,161	4,386	70,179	74,565	110,726
Contributed media and services (note 2)	5,000	9,964,665	—	9,969,665	244,033	118,231	362,264	10,331,929
Salaries, professional services and related costs	747,398	647,670	186,849	1,581,917	560,548	593,893	1,154,441	2,736,358
Public information costs	—	209,535	—	209,535	—	574,476	574,476	784,011
Supplies and mail	—	—	—	—	34,813	134,676	169,489	169,489
Meetings, travel, and related costs	—	—	—	—	8,388	47,293	55,681	55,681
Insurance	11,061	9,482	2,766	23,309	8,297	7,902	16,199	39,508
Printing	—	—	—	—	33,602	207,569	241,171	241,171
Depreciation	18,523	15,877	4,630	39,030	13,892	13,231	27,123	66,153
Marketing and advertising	844	373,355	—	374,199	11,357	292,383	303,740	677,939
Rent	51,969	44,545	12,992	109,506	38,977	37,121	76,098	185,604
Utilities and maintenance	12,578	10,781	3,144	26,503	9,433	8,984	18,417	44,920
Bank and credit card fees	—	—	—	—	—	216,896	216,896	216,896
Information technology and Web site	7,480	72,663	—	80,143	102,219	65,230	167,449	247,592
Other	40,723	16,692	2,517	59,932	112,430	7,549	119,979	179,911
Total expenses	\$ 24,673,145	11,401,426	261,711	36,336,282	1,182,375	2,395,881	3,578,256	39,914,538
Direct benefits to donors								371,093
Total expenses and direct benefits to donors								\$ 40,285,631

See accompanying notes to financial statements.

MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION
(a/k/a The Lustgarten Foundation for Pancreatic Cancer Research)

Statements of Cash Flows

Years ended June 30, 2020 and 2019

	2020	2019
Cash flows from operating activities:		
Decrease in net assets	\$ (9,849,248)	(7,507,343)
Adjustments to reconcile decrease in net assets to net cash provided by operating activities:		
Net appreciation in fair value of investments	(46,899)	(4,350,528)
Contributed marketable securities	(121,633)	(150,662)
Depreciation	72,210	66,153
Changes in assets and liabilities:		
Contributions receivable	12,319,927	16,511,715
Prepaid expenses and other assets	56,924	(7,883)
Accounts payable and accrued expenses	(338,110)	(2,260)
Deferred revenue	168,158	149,302
Grants payable	1,235,604	575,571
Deferred rent obligation	11,228	16,226
Net cash provided by operating activities	3,508,161	5,300,291
Cash flows from investing activities:		
Proceeds from sale of investments	35,999,987	99,364,883
Purchases of investments	(43,442,226)	(107,263,602)
Reclassified cash equivalents held within investments	—	(4,227,069)
Purchase of fixed assets	(1,400)	(55,311)
Net cash used in investing activities	(7,443,639)	(12,181,099)
Net decrease in cash and cash equivalents	(3,935,478)	(6,880,808)
Cash and cash equivalents at beginning of year	5,845,815	12,726,623
Cash and cash equivalents at end of year	\$ 1,910,337	5,845,815
Noncash activities:		
Contributed marketable securities	\$ 121,633	150,662
Contributed media	3,656,075	10,054,276
Contributed services	290,061	277,653

See accompanying notes to financial statements.

MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION
(a/k/a The Lustgarten Foundation for Pancreatic Cancer Research)

Notes to Financial Statements

June 30, 2020 and 2019

(1) Description of Organization and Summary of Significant Accounting Policies

The Marc Lustgarten Pancreatic Cancer Foundation (a/k/a The Lustgarten Foundation for Pancreatic Cancer Research) (the Foundation), formed in 1998, is a not-for-profit organization whose main office is located in Woodbury, New York.

The mission of the Foundation is to cure pancreatic cancer by:

- Funding scientific and clinical research related to the diagnosis, treatment, and prevention of pancreatic cancer.
- Providing research information and clinical support services to patients, caregivers, and individuals at high risk.
- Increasing public awareness and hope for those dealing with this disease.

The significant accounting policies followed by the Foundation are described below:

(a) Current environment

In March 2020, the World Health Organization declared the novel coronavirus (COVID-19) a pandemic. The outbreak of the disease has affected travel, commerce, and financial markets globally, including in the United States. The continued spread of COVID-19 and its impact on social interaction, travel, economies, and financial markets may adversely affect operations and financial condition, including, among other things, the ability of the Foundation to conduct its operations and/or the cost of operations and financial markets impacting investments valuation and interest rates.

Commencing in March 2020, all in-person events were suspended and continued to be suspended through the entire 2020 fiscal year. Given the uncertainty over the progression of the virus and governmental emergency directives, there is no timetable for when events and operations will return to normal.

The COVID-19 pandemic has negatively affected national, state, and local economies and global financial markets. While the financial impact on the Foundation cannot be quantified at this time, the pandemic may have a material adverse effect on the current and future financial profile and operating performance of the Foundation. The Foundation continues to monitor the course of the pandemic and is prepared to take additional measures to protect the health of the Foundation community and promote the continuity of its mission.

(b) Basis of Presentation

The accompanying financial statements have been prepared on the accrual basis of accounting.

(c) Net Assets

Net assets, revenue, and gains are classified based on the existence or absence of donor-imposed restrictions, as follows:

(i) Net assets without donor restrictions

Net assets not subject to donor-imposed restrictions.

MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION
(a/k/a The Lustgarten Foundation for Pancreatic Cancer Research)

Notes to Financial Statements

June 30, 2020 and 2019

(ii) *Net assets with donor restrictions*

Net assets subject to donor-imposed restrictions that will be met either by actions of the Foundation and/or the passage of time

When a donor restriction expires, that is, when a time restriction ends or a purpose restriction is met, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported as net assets released from donor restrictions.

(d) Cash and Cash Equivalents

The Foundation considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents, except for those highly liquid investments held by investment managers for investment purposes. Cash equivalents at June 30, 2020 and 2019 were \$26,224 and \$31,723, respectively. The Foundation's cash equivalents are demand deposits placed within money market funds and Bank Deposit Programs (the BDPs). The BDPs are cash sweep features whereby free credit balances are automatically deposited into accounts established for clients.

(e) Investments and Fair Value

Investments are primarily debt and equity securities and are stated at fair value based on quoted market prices. The cost basis for securities received through gift is the fair value at the date of donation.

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three levels of the fair value hierarchy are as follows:

- Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that a reporting entity has the ability to access at the measurement date.
- Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
- Level 3 inputs are unobservable inputs for the asset or liability.

The level in the fair value hierarchy within which a fair measurement in its entirety falls is based on the lowest-level input that is significant to the fair value measurement.

(f) Contributions

Contributions to the Foundation are recorded as revenues at the earlier of the receipt of unconditional pledges or of cash or other assets. Gifts of cash and other assets are reported as restricted support if they are received with donor stipulations that limit the use of the donated assets. Donor-restricted contributions, whose restrictions are met within the same year as received, are reflected as contributions without donor restrictions. In the absence of donor specification that income and gains on donated funds are restricted, such income and gains are reported as increases of net assets without donor restrictions. Contributions are classified as conditional if a barrier must be overcome to be entitled to the funds or if a right of return of assets transferred or a right of release of a promisor's

MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION
(a/k/a The Lustgarten Foundation for Pancreatic Cancer Research)

Notes to Financial Statements

June 30, 2020 and 2019

obligation to transfer assets exists. Conditional pledges are not included as support until the conditions are substantially met

(g) Special Events Revenue

Special event revenue is shown net of costs of direct benefits to donors.

(h) Functional Allocation of Expenses

The costs of providing program and supporting services have been reported on a functional and natural basis. The majority of the Foundation's expenses are charged on the direct-identification method. Those expenses that cannot be directly identified have been allocated to program and supporting services based on a percentage established by management, either based on square footage or other reasonable basis consistent with the benefit derived by each program.

(i) Software, Furniture, and Equipment

Software, furniture, and equipment are stated at cost and depreciated over their estimated useful lives of three to eight years on a straight-line basis.

(j) Grants

Grants that have been awarded are recorded as expenses, unless deemed to be conditional. Conditional grants are noted in commitments (note 5). The Foundation expects that the grants payable balance of \$8,774,834 and \$7,539,230 at June 30, 2020 and 2019, respectively, will be substantially paid within one year.

(k) Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

(l) Income Taxes

The Foundation has received a final determination letter from the Internal Revenue Service stating that the Foundation is exempt from federal income tax under Section 501(c)(3). The Foundation is treated as a public charity as defined in Sections 509(a)(1) and 170(b)(1)(A)(vi).

The Foundation follows the provisions of Accounting Standards Codification (ASC) Subtopic 740-10, *Income Taxes – Overall (ASC 740-10)*, relating to uncertainty in income taxes. For the Foundation, ASC 740-10 is primarily applicable to the incurrence of unrelated business income tax attributable to certain of its investments. ASC 740-10 establishes a minimum threshold for financial statement recognition of the benefits of positions taken, or expected to be taken, in filing tax returns. It requires the evaluation of tax positions taken or expected to be taken, in the course of preparing the Foundation's income tax returns to determine whether the tax positions are "more likely than not" of being sustained by the applicable tax authority. Tax positions not deemed to meet the more-likely

MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION
(a/k/a The Lustgarten Foundation for Pancreatic Cancer Research)

Notes to Financial Statements

June 30, 2020 and 2019

than-not threshold are recorded as tax expense. For the years ended June 30, 2020 and 2019, the Foundation has not identified or provided for any such positions.

(m) Recently adopted Accounting Standards

In 2020, the Foundation adopted Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No. 2018-08, *Not-for-Profit Entities – Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made* for contributions received. This update helps an entity evaluate whether it should account for a grant (or similar transaction) as a contribution or as an exchange transaction. The update also clarifies and expands the criteria for determining whether a contribution is conditional, which may delay recognition of contribution revenue (recipient) or expenses (resource provider). The adoption did not have a significant impact on the financial statements. The guidance for contributions made is required to be adopted for the year ending June 30, 2021.

(n) Recent Accounting Pronouncements

In February 2016, the FASB issued ASU No. 2016-02, *Leases*, which require lessees to recognize a lease liability and a right of use asset for all lease obligations with the exception for short-term leases (less than 12 months). The lease liability will represent the lessee's obligation to make lease payments arising from the lease measured on a discounted basis. The right of use asset will represent the lessee's right to use or control a specified asset during the lease term. The new standard is effective for the Foundation for the year ending June 30, 2023. The Foundation is evaluating the impact of adopting this guidance on its financial statements.

(o) Reclassification

Certain prior year amounts have been reclassified to conform to the current year presentation.

(2) Contributed Media and Services

Audit and various program services were donated to the Foundation totaling \$290,061 and \$277,653 for the years ended June 30, 2020 and 2019, respectively. Contributed services are recognized as revenue and expenses in the accompanying financial statements, based upon their estimated fair values.

Contributions have been made to the Foundation in the form of pro bono advertising time and space (contributed media). The Foundation's policy for recognizing contributed media is to recognize the contributed asset if it is determined that the contributions are for the benefit of the Foundation, help the Foundation communicate its message, and the Foundation has significant influence over the creative product. The Foundation has recognized the fair value of contributed media in the financial statements of approximately \$3.7 million and \$10.1 million for the years ended June 30, 2020 and 2019, respectively. The fair value of the contributed media has been estimated by using the number of spots aired and the market rate per spot at the time of airing.

MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION
(a/k/a The Lustgarten Foundation for Pancreatic Cancer Research)

Notes to Financial Statements

June 30, 2020 and 2019

(3) Contributions Receivable

Contributions receivable at June 30, 2020 and 2019 is scheduled to be collected as follows:

	<u>2020</u>	<u>2019</u>
Less than one year	\$ 318,852	12,626,868
One to five years	—	12,604
	<u>318,852</u>	<u>12,639,472</u>
Unamortized discount (1.75%)	—	(693)
	<u>\$ 318,852</u>	<u>12,638,779</u>

At June 30, 2019, \$12,225,351 of contributions receivable represented bequests receivable, of which approximately \$11.8 million of the bequests receivable was due from two estates. These bequests receivable balance was received in fiscal year 2020. No similar bequests were received by the Foundation in fiscal year 2020.

(4) Investments at fair value

Investments at fair value at June 30, 2020 and 2019 are summarized as follows:

	<u>2020</u>	<u>2019</u>
Level 1:		
Equity securities	\$ 51,151,252	42,918,480
Level 2:		
Corporate bonds	11,053,462	14,450,765
U.S. government bonds	24,534,193	14,783,480
Cash equivalents	<u>1,243,273</u>	<u>8,218,684</u>
	<u>\$ 87,982,180</u>	<u>80,371,409</u>

At June 30, 2020 and 2019, there were no investments that were measured using Level 3 inputs.

MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION
(a/k/a The Lustgarten Foundation for Pancreatic Cancer Research)

Notes to Financial Statements

June 30, 2020 and 2019

(5) Commitments

The Foundation had commitments of \$43,292,539 and \$29,710,588 for conditional grants as of June 30, 2020 and 2019, respectively. Such grants become payable once the underlying conditions have been achieved, which is expected to be as follows:

Fiscal year	Amount
2021	\$ 21,811,790
2022	12,561,925
2023	6,668,824
2024	2,250,000
Total	\$ 43,292,539

In 2017, a board-designated fund was established to cover the Foundation's administrative expenses for the next several years. The fund was established utilizing accumulated interest, dividends, investment earnings, and royalty income. All remaining net assets without donor restrictions were reserved for research.

The Foundation is obligated under two operating leases for office equipment expiring in 2022 and 2024. Lease expense amounted to \$10,705 and \$10,760 for the years ended June 30, 2020 and 2019, respectively. Future minimum lease payments required under the operating leases are as follows:

2021	\$ 12,252
2022	11,154
2023	10,788
2024	3,596
Total future lease expense	\$ 37,790

In June 2017, the Foundation entered into a lease agreement for new office space and relocated its headquarters. The lease, which expires in July 2027, includes annual rent escalations and a rent credit equivalent to two months' rent. Rent expense is recorded on a straight-line basis with an associated deferred rent obligation. Rent expense was \$185,276 and \$185,604 for the years ended June 30, 2020 and 2019, respectively.

MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION
(a/k/a The Lustgarten Foundation for Pancreatic Cancer Research)

Notes to Financial Statements

June 30, 2020 and 2019

The future minimum rental payments required under the office space operating lease are as follows:

2021	\$	176,701
2022		182,002
2023		187,462
2024		193,086
2025		198,879
Thereafter		433,460
Total future lease expense	\$	1,371,590

(6) Benefit Plans

Cablevision Systems Corporation sponsored a noncontributory, qualified defined-benefit cash balance pension plan (the Pension Plan) in which employees of the Foundation participated. Effective June 1, 2016, the Foundation's employee balances in the Pension Plan, as well as the related plan assets and liabilities, were transferred into the MSG Holdings, L.P. Cash Balance Pension Plan (MSG Pension Plan), which is a single-employer plan that is frozen to future benefit accruals. The Foundation has no assets or liabilities or going-forward obligations with respect to the MSG Pension Plan.

(7) Time or Purpose Restricted Net Assets

Time or purpose restricted net assets of \$8,594,431 were released for research grants during the years ended June 30, 2019. Time or purpose restricted net assets of \$55,645 and \$73,429 have been released due to donor-imposed time restrictions being met during the years ended June 30, 2020 and 2019, respectively. Time or purpose restricted net assets are available for the following purposes at June 30, 2020 and 2019:

		2020	2019
Annual scientific conference	\$	40,000	30,000
Time restricted		324,000	25,645
	\$	364,000	55,645

MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION
(a/k/a The Lustgarten Foundation for Pancreatic Cancer Research)

Notes to Financial Statements

June 30, 2020 and 2019

(8) Liquidity and Availability

The Foundation manages its liquidity by developing annual operating budgets that provide sufficient funds for general expenditures. As of June 30, 2020 and 2019, the financial assets available within one year of the financial position date for general expenditures such as operating expenses are as follows:

	<u>2020</u>	<u>2019</u>
Cash and cash equivalents	\$ 1,910,337	5,845,815
Investments	87,982,180	80,371,409
Contributions receivable, due within one year	318,852	12,626,868
	<u>\$ 90,211,369</u>	<u>98,844,092</u>

As part of the Foundation's liquidity management, the board has designated \$17,888,840 and \$21,280,960 as of June 30, 2020 and 2019, respectively, in funds without donor restrictions for administrative expenses. The Foundation also invests cash in excess of daily requirements in short-term investments. In addition to the financial assets available within one year, current year operating revenues will fund annual expenditures.

(9) Subsequent Events

In connection with the preparation of the financial statements, the Foundation evaluated subsequent events from June 30, 2020 through May 14, 2021, which was the date the financial statements were available for issuance, and concluded that no additional disclosures were required.